Olverembatinib

CAT: 0804-HY-15666-01Size: 1 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-15666-01Size:1 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity[1]. Olverembatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

CAS Number

1257628-77-5

Product Name Alternative

GZD824; HQP1351

UNSPSC

12352005

Hazard Statement

H302

Target

Bcr-Abl

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gzd824.html

Concentration

10mM

Purity

99.47

Solubility

DMSO : 41.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C(NN=C5)C5=C4)=C3

Molecular Formula

C29H27F3N6O

Molecular Weight

532.56

Precautions

H302

References & Citations

[1]Ren X, Pan X, Zhang Z, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14;56 (3) :879-94.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Chemical Information

Olverembatinib

HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).

CAS Number	1257628-77-5
PubChem CID	51038269
IUPAC Name	4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[5,4-b]pyridin-5-yl)ethynyl]benzamide
Molecular Formula	C29H27F3N6O
Molecular Weight	532.6
XLogP	4.6
Topological Polar Surface Area	77.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Heavy Atom Count	39
Formal Charge	0
Complexity	910

SMILES

CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4

InChI

InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)

InChIKey

TZKBVRDEOITLRB-UHFFFAOYSA-N

Chemical Structure

2D Structure

CAS: 1257628-77-5

CID: 51038269

Formula: C29H27F3N6O

MW: 532.6

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	532.6
XLogP3	4.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	532.21984399
Monoisotopic Mass	532.21984399
Topological Polar Surface Area	77.2 Å²
Heavy Atom Count	39
Formal Charge	0
Complexity	910
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Alternative Products

Catalog	Name
E7062	Olverembatinib
T2429-01	Olverembatinib dimesylate
407111	Olverembatinib (GZD824)
S7194-25mg	Olverembatinib (GZD824) dimesylate
A16264-2	Olverembatinib (GZD824) 2mg
A16264-1	Olverembatinib (GZD824) 1mg
A16264-100	Olverembatinib (GZD824) 100mg
A16264-25	Olverembatinib (GZD824) 25mg
A16264-10mM-D	Olverembatinib (GZD824) 10mM * 1mL in DMSO

Olverembatinib

Chemical Information

Alternative Products

Popular Products